Optimization of an Exploratory Oncology Panel for Immunoprofiling Tissues in the Tumor
Microenvironment using CO-Detection by indEXing (CODEX) methodology
Davis P. John1, Saxon A. Rodriguez2, Salome A. McAllen2, Edwin R. Parra2
1. The University of Texas at Dallas, Richardson, TX, 2. Department of Translational Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Results

Background
•

Cancer immunotherapy is revolutionizing cancer treatment by aiding
the natural ability of the immune system to identify and defend against
tumors.

•

In order to better design cancer therapeutics and advance clinical care,
the immunoregulatory proteins involved in immune checkpoints and
immunosuppression must be immunoprofiled.

•

We used highly multiplexed tissue imaging technologies, such as
CODEX (CO-Detection by indEXing), which allows more than 40
antibody markers to be placed and analyzed on tissues.

•

Herein, we describe the optimization, validation and application of a 27antibody panel used for multiplexed immunophenotyping.
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Figure 3. Heat map showing the presence of various markers in different cell-types.

Figure 2. Antibodies included in the CODEX panel.

Hypothesis
We hypothesize that the various markers will stain in similar patterns
with both chromogenic IHC and CODEX, and that the antibodies will
correctly recognize various lymphoid, myeloid, structural and immune
cells in order to effectively depict the immunoprofile.

Figure 1. Workflow of the application of the CODEX panel.
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Discussion and Conclusion
•
DAPI
CK

DAPI
CD3

DAPI
CD107

DAPI
CD8

DAPI
CD20

DAPI
KI67

DAPI
CK
KI67
CD3
CD20
CD8
CD107

First cycle

Non-small cell lung cancer

•

Second cycle

•
•
•
•
•
•
•

Figure 5. Example of cycles staining in human reactive tonsil and non-small cell lung cancer case .
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Methods

Figure 4. Percent of immune and tumor cells that
express various immunoregulatory proteins.

Reactive tonsil

•
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We successfully optimized the various markers to obtain similar
staining patterns with both chromogenic IHC and CODEX. PDL1 was predominantly expressed on the cell membranes of
epithelial cells on tonsil tissue. Other immune checkpoint
proteins were observed in various immune cells. In control tonsil,
CK was expressed by epithelial cells, and among cells
surrounding the germinal centers, the T cell marker CD3 was
most abundant, followed by CD8, Granzyme B, CD45RO,
FOXP3. PD-1 was predominantly distributed within the germinal
center of the tonsil tissue. We are continuing to test the other
markers in the panel.
Multiplexed immunophenotyping approaches reveal key insight
into identifying therapeutic mechanisms. A comprehensive
immunoprofile will advance our understanding of how various
factors can determine disease progression, resistance and
response to immunotherapies and facilitate the development of
new treatment approaches.
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